Racial Disparities in Use of Diabetes Technology Widen among Medicare Enrollees

While use of insulin pumps and CGM increased over a 3-year study period for all racial-ethnic groups, the inequities were significant between White adults and all others.

CGM-measured Glucose Variability Associated with Diabetes Micro- and Macrovascular Complications

Glycemic variability and low time in range were associated with retinopathy, nephropathy, neuropathy, and CVD in a cohort of more than 20 000 persons, most with T2D.

Blood Glucose Levels in T2D: 42 Factors that Make a Difference

These 42 factors that affect blood glucose are listed in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.

Real Time CGM Improves A1c, Time in Range in T2D Patients on Less Intensive Treatment

CGMs have revolutionized diabetes management for patients and healthcare providers alike. This slide show summarizes the most recent integration enhancements.

Current Advances in Continuous Glucose Monitoring Technology

Greatest improvements in A1c, %TIR, and other glycemic parameters were seen in patients treated with ≤1 medication, in another challenge to current payer restrictions.

Continuous Glucose Monitoring for Type 2 Diabetes in Primary Care: 2021 Research Review

Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.

DIABETES: 2021 Clinical Focus Collection

From expert interviews on novel treatments and FDA approvals to tests of your clinical knowledge and guideline recall, Patient Care Online summarizes the progress made in diabetes management in 2021.

Cardiovascular Risk Found Greatest in Prediabetes A1c Range

For individuals with A1c of 6.4-6.5%, just below the threshold for diabetes, risk of MACE was higher than for any other subgroup with A1c values ranging from 5.8-6.8%.

Tom Martens, MD, Talks about the Vision for CGM as Part of Primary Care for Type 2 Diabetes

MOBILE study lead author Tom Martens, MD, talks about the inherent benefits of CGM for T2D patients on basal insulin treated in primary care and also the challenges to this vision of patient care.

CGM vs BGM in T2 Diabetes: MOBILE Study Findings with PI Thomas W. Martens, MD

MOBILE study lead author Thomas W. Martens, MD, discusses results of the study which was designed to capture CGM results in real-world primary care practice.

Standards of Medical Care in Diabetes – 2022

First of its kind: Use of Advanced Technology in Management of Persons with Diabetes Mellitus

AACE Comprehensive Type 2 Diabetes Management Algorithm

EASD Collected Guidelines, Consensus Reports in Diabetologia

The 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA*Guidelines on the Management of Blood Cholesterol in Diabetes

Diabetes Type 2: A Collection of Best Content from JAFP

Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy for Nonpregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement Update from the American College of Physicians

Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement

Diabetes Clinical Tools and Patient Management

Professional Resources on Glucose Monitoring

Diabetes Resources for Patients and Families

Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association

Blood sugar testing and control

Diabetes Self-Management Patient Education Materials

Diabetes Patient Care and Health Information

Diabetes Patient Education Hub

Diabetes Basics and Beyond

Making Sense of Diabetes

Detailed review for patients including cost, insurance coverage, ease of use, special features

CGM Benefits Type 2 Diabetes Management, 2 New Studies Show

How Using Diabetes Patient Assistance Programs Can Help You Afford Insulin and Oral Meds

© 2023 MJH Life Sciences

All rights reserved.